Alnylam Pharmaceuticals Inc Insider Trading

ALNY

Last 12 months

Insiders sold $44M and bought nothing on the open market.

63% of the selling was scheduled in advance under 10b5-1 plans. Chief Executive Officer Yvonne Greenstreet sold $3.48M on Jan 12, 11% of their stake, outside a plan. The last open-market buy by an executive or director was in Oct 2024.

Net open-market

−$44M

0 buys · 26 sales

Under a 10b5-1 plan

63%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Oct 2024

Oct 17, 2024

Get an email when ALNY's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 2	Bryan Supran EVP, CLO and Secretary	SoldNo plan	1,758	$226.88	399K	12%	Form 4
Jun 1	David E I Pyott Director	Sold10b5-1 plan 5 parts	3,830	$299.18 average	$1.15M	11%	Form 4
Apr 2 – 6	Melissa McLaughlin Chief Human Resources Officer	Sold10b5-1 plan 14 parts	3,910	$325.92 average	$1.27M	29%	Form 4
Mar 4 – 5	Pushkal Garg EVP Chief R&D	Sold10b5-1 plan 12 parts	4,713	$323.53 average	$1.52M	20%	Form 4
Mar 4 – 5	Kevin Joseph Fitzgerald CSO & EVP, Head of Research	Sold10b5-1 plan 12 parts	1,291	$323.54 average	418K	5.8%	Form 4
Mar 4	Yvonne Greenstreet Chief Executive Officer	SoldNo plan 8 parts	2,933	$323.08 average	948K	3.0%	Form 4
Mar 4	Jeffrey V. Poulton EVP, Chief Financial Officer	SoldNo plan 8 parts	2,468	$323.08 average	797K	3.8%	Form 4
Mar 4	Tolga Tanguler EVP, Chief Commercial Officer	SoldNo plan 8 parts	2,309	$323.08 average	746K	6.3%	Form 4
Mar 2 – 3	Pushkal Garg EVP Chief R&D	Sold10b5-1 plan 14 parts	3,492	$323.63 average	$1.13M	13%	Form 4
Mar 2 – 3	Kevin Joseph Fitzgerald CSO & EVP, Head of Research	Sold10b5-1 plan 14 parts	3,250	$323.62 average	$1.05M	13%	Form 4
Mar 2	Jeffrey V. Poulton EVP, Chief Financial Officer	SoldNo plan 10 parts	2,206	$327.65 average	723K	3.3%	Form 4
Mar 2	Tolga Tanguler EVP, Chief Commercial Officer	SoldNo plan 10 parts	1,598	$327.65 average	524K	4.2%	Form 4
Mar 2	Yvonne Greenstreet Chief Executive Officer	SoldNo plan 10 parts	6,799	$327.65 average	$2.23M	6.4%	Form 4
Feb 27	Pushkal Garg EVP Chief R&D	Sold10b5-1 plan 5 parts	4,627	$331.34 average	$1.53M	17%	Form 4
Feb 13 – 17	Kevin Joseph Fitzgerald CSO & EVP, Head of Research	Sold10b5-1 plan 2 parts	4,000	$321.24 average	$1.28M	16%	Form 4
Feb 13	Pushkal Garg EVP Chief R&D	SoldNo plan	2,242	$310.08	695K	8.1%	Form 4
Feb 13	Yvonne Greenstreet Chief Executive Officer	SoldNo plan	6,958	$310.08	$2.16M	7.5%	Form 4
Feb 13	Tolga Tanguler EVP, Chief Commercial Officer	SoldNo plan	1,959	$310.08	607K	5.8%	Form 4
Feb 13	Jeffrey V. Poulton EVP, Chief Financial Officer	SoldNo plan	2,242	$310.08	695K	3.6%	Form 4
Jan 12 – 13	Kevin Joseph Fitzgerald CSO & EVP, Head of Research	Sold10b5-1 plan 27 parts	3,800	$367.37 average	$1.4M	15%	Form 4
Jan 12	Pushkal Garg EVP Chief R&D	SoldNo plan 21 parts	1,510	$362.87 average	548K	6.1%	Form 4
Jan 12	Yvonne Greenstreet Chief Executive Officer	SoldNo plan 21 parts	9,577	$362.86 average	$3.48M	11%	Form 4
Jan 12	Jeffrey V. Poulton EVP, Chief Financial Officer	SoldNo plan 21 parts	2,780	$362.87 average	$1.01M	4.6%	Form 4
Jan 12	Tolga Tanguler EVP, Chief Commercial Officer	SoldNo plan 21 parts	1,510	$362.87 average	548K	4.8%	Form 4
Nov 17, 2025	Kevin Joseph Fitzgerald CSO & EVP, Head of Research	Sold10b5-1 plan 11 parts	12,128	$452.18 average	$5.48M	36%	Form 4
Nov 12, 2025 – Nov 13, 2025	Yvonne Greenstreet Chief Executive Officer	Sold10b5-1 plan 20 parts	25,650	$452.75 average	$11.6M	28%	Form 4
Oct 2, 2025 – Oct 3, 2025	Pushkal Garg EVP Chief R&D	Sold10b5-1 plan 17 parts	5,959	$451.76 average	$2.69M	22%	Form 4
Oct 2, 2025	Jeffrey V. Poulton EVP, Chief Financial Officer	SoldNo plan 12 parts	3,821	$452.05 average	$1.73M	6.6%	Form 4
Oct 2, 2025	Yvonne Greenstreet Chief Executive Officer	SoldNo plan 12 parts	8,924	$452.05 average	$4.03M	12%	Form 4
Oct 2, 2025	Tolga Tanguler EVP, Chief Commercial Officer	SoldNo plan 12 parts	1,405	$452.05 average	635K	4.9%	Form 4
Oct 2, 2025	Kevin Joseph Fitzgerald CSO & EVP, Head of Research	SoldNo plan 12 parts	2,441	$452.05 average	$1.1M	8.7%	Form 4
Sep 9, 2025	Colleen F Reitan Director	Sold10b5-1 plan 16 parts	18,000	$467.60 average	$8.42M	96%	Form 4
Aug 29, 2025	Tolga Tanguler EVP, Chief Commercial Officer	Sold10b5-1 plan 6 parts	3,474	$448.37 average	$1.56M	12%	Form 4
Aug 18, 2025 – Aug 19, 2025	Pushkal Garg EVP Chief R&D	Sold10b5-1 plan 14 parts	2,851	$455.89 average	$1.3M	12%	Form 4
Aug 18, 2025	Tolga Tanguler EVP, Chief Commercial Officer	SoldNo plan 8 parts	1,396	$453.27 average	633K	4.5%	Form 4
Aug 18, 2025	Jeffrey V. Poulton EVP, Chief Financial Officer	SoldNo plan 8 parts	2,274	$453.27 average	$1.03M	4.3%	Form 4
Aug 18, 2025	Yvonne Greenstreet Chief Executive Officer	SoldNo plan 8 parts	6,979	$453.27 average	$3.16M	11%	Form 4
Aug 18, 2025	Kevin Joseph Fitzgerald CSO & EVP, Head of Research	SoldNo plan 8 parts	1,396	$453.27 average	633K	5.7%	Form 4
Aug 18, 2025	Michael W Bonney Director	Sold10b5-1 plan	11,250	$450.00	$5.06M	35%	Form 4
Aug 14, 2025	Dennis A Ausiello Director	Sold10b5-1 plan 11 parts	31,448	$436.58 average	$13.7M	88%	Form 4

Oct 2No plan
Bryan Supran
EVP, CLO and Secretary · sold 1,758 at $226.88
399K
12% of stake
Jun 110b5-1 plan
David E I Pyott
Director · sold 3,830 at avg $299.18
$1.15M
11% of stake
Apr 2 – 610b5-1 plan
Melissa McLaughlin
Chief Human Resources Officer · sold 3,910 at avg $325.92
$1.27M
29% of stake
Mar 4 – 510b5-1 plan
Pushkal Garg
EVP Chief R&D · sold 4,713 at avg $323.53
$1.52M
20% of stake
Mar 4 – 510b5-1 plan
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research · sold 1,291 at avg $323.54
418K
5.8% of stake
Mar 4No plan
Yvonne Greenstreet
Chief Executive Officer · sold 2,933 at avg $323.08
948K
3.0% of stake
Mar 4No plan
Jeffrey V. Poulton
EVP, Chief Financial Officer · sold 2,468 at avg $323.08
797K
3.8% of stake
Mar 4No plan
Tolga Tanguler
EVP, Chief Commercial Officer · sold 2,309 at avg $323.08
746K
6.3% of stake
Mar 2 – 310b5-1 plan
Pushkal Garg
EVP Chief R&D · sold 3,492 at avg $323.63
$1.13M
13% of stake
Mar 2 – 310b5-1 plan
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research · sold 3,250 at avg $323.62
$1.05M
13% of stake
Mar 2No plan
Jeffrey V. Poulton
EVP, Chief Financial Officer · sold 2,206 at avg $327.65
723K
3.3% of stake
Mar 2No plan
Tolga Tanguler
EVP, Chief Commercial Officer · sold 1,598 at avg $327.65
524K
4.2% of stake
Mar 2No plan
Yvonne Greenstreet
Chief Executive Officer · sold 6,799 at avg $327.65
$2.23M
6.4% of stake
Feb 2710b5-1 plan
Pushkal Garg
EVP Chief R&D · sold 4,627 at avg $331.34
$1.53M
17% of stake
Feb 13 – 1710b5-1 plan
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research · sold 4,000 at avg $321.24
$1.28M
16% of stake
Feb 13No plan
Pushkal Garg
EVP Chief R&D · sold 2,242 at $310.08
695K
8.1% of stake
Feb 13No plan
Yvonne Greenstreet
Chief Executive Officer · sold 6,958 at $310.08
$2.16M
7.5% of stake
Feb 13No plan
Tolga Tanguler
EVP, Chief Commercial Officer · sold 1,959 at $310.08
607K
5.8% of stake
Feb 13No plan
Jeffrey V. Poulton
EVP, Chief Financial Officer · sold 2,242 at $310.08
695K
3.6% of stake
Jan 12 – 1310b5-1 plan
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research · sold 3,800 at avg $367.37
$1.4M
15% of stake
Jan 12No plan
Pushkal Garg
EVP Chief R&D · sold 1,510 at avg $362.87
548K
6.1% of stake
Jan 12No plan
Yvonne Greenstreet
Chief Executive Officer · sold 9,577 at avg $362.86
$3.48M
11% of stake
Jan 12No plan
Jeffrey V. Poulton
EVP, Chief Financial Officer · sold 2,780 at avg $362.87
$1.01M
4.6% of stake
Jan 12No plan
Tolga Tanguler
EVP, Chief Commercial Officer · sold 1,510 at avg $362.87
548K
4.8% of stake
Nov 17, 202510b5-1 plan
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research · sold 12,128 at avg $452.18
$5.48M
36% of stake
Nov 12, 2025 – Nov 13, 202510b5-1 plan
Yvonne Greenstreet
Chief Executive Officer · sold 25,650 at avg $452.75
$11.6M
28% of stake
Oct 2, 2025 – Oct 3, 202510b5-1 plan
Pushkal Garg
EVP Chief R&D · sold 5,959 at avg $451.76
$2.69M
22% of stake
Oct 2, 2025No plan
Jeffrey V. Poulton
EVP, Chief Financial Officer · sold 3,821 at avg $452.05
$1.73M
6.6% of stake
Oct 2, 2025No plan
Yvonne Greenstreet
Chief Executive Officer · sold 8,924 at avg $452.05
$4.03M
12% of stake
Oct 2, 2025No plan
Tolga Tanguler
EVP, Chief Commercial Officer · sold 1,405 at avg $452.05
635K
4.9% of stake
Oct 2, 2025No plan
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research · sold 2,441 at avg $452.05
$1.1M
8.7% of stake
Sep 9, 202510b5-1 plan
Colleen F Reitan
Director · sold 18,000 at avg $467.60
$8.42M
96% of stake
Aug 29, 202510b5-1 plan
Tolga Tanguler
EVP, Chief Commercial Officer · sold 3,474 at avg $448.37
$1.56M
12% of stake
Aug 18, 2025 – Aug 19, 202510b5-1 plan
Pushkal Garg
EVP Chief R&D · sold 2,851 at avg $455.89
$1.3M
12% of stake
Aug 18, 2025No plan
Tolga Tanguler
EVP, Chief Commercial Officer · sold 1,396 at avg $453.27
633K
4.5% of stake
Aug 18, 2025No plan
Jeffrey V. Poulton
EVP, Chief Financial Officer · sold 2,274 at avg $453.27
$1.03M
4.3% of stake
Aug 18, 2025No plan
Yvonne Greenstreet
Chief Executive Officer · sold 6,979 at avg $453.27
$3.16M
11% of stake
Aug 18, 2025No plan
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research · sold 1,396 at avg $453.27
633K
5.7% of stake
Aug 18, 202510b5-1 plan
Michael W Bonney
Director · sold 11,250 at $450.00
$5.06M
35% of stake
Aug 14, 202510b5-1 plan
Dennis A Ausiello
Director · sold 31,448 at avg $436.58
$13.7M
88% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ALNY, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ALNY

CompareIntrinsic value

BMRNBiomarin Pharmaceutical Inc.

$57.13+2.64%47

PRGOPerrigo Company plc

$15.83+0.83%17

UTHRUnited Therapeutics Corporation

$608.49+1.19%78

AMRXAmneal Pharmaceuticals Inc.

$19.95-1.29%57

JAZZJazz Pharmaceuticals plc

$234.66+2.14%58

RPRXRoyalty Pharma plc

$67.56+1.75%19

ELANElanco Animal Health Incorporated

$25.31+3.01%46

SRPTSarepta Therapeutics Inc.

$18.99+2.43%51

Held by ETFs

ALNY is in 235 US ETFs. The largest of them, with ALNY's weight in each:

Spot a number that looks wrong? Check it in ALNY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ALNY

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.